Effectiveness of Single-Dose Rifapentine in Household Contacts of Leprosy Patients under Low Endemic Situations in China: A Cluster-Randomised Controlled Trial
Le Wang,Hong-Sheng Wang,Liangbin Yan,Meiwen Yu,Jun Yang,Jinlan Li,Junhua Li,Yong Ning,Haiqin Jiang,Ying Shi,Wenyue Zhang,Li Xiong,Jie Liu,Yanfei Kuang,Hao Wang,Jun He,De Wang,Bin Li,Yangying Liu,Tiejun Shui,Ying Wang,Huan Chen,Xiaowei Sha,Heng Long,Xiaojin Yu,Chong Shen,Jianping Shen,Xueyuan Yang,Heng Gu,Guocheng Zhang,Baoxi Wang
DOI: https://doi.org/10.2139/ssrn.4074662
2022-01-01
SSRN Electronic Journal
Abstract:Background: Previous studies suggest protection of a single dose of rifampicin(SDR) from developing leprosy among close contacts. This study aimed to evaluate the effectiveness of a single dose of rifapentine(SDL) to prevent leprosy in household contacts (HHCs) of leprosy cases in areas of low epidemic leprosy in China.Methods: In this cluster-randomised controlled trial, we randomised and allocated 207 clusters (counties) into three arms, the eligible HHCs of patients diagnosed with leprosy since 2010 received SDL, SDR or no post-exposure prophylaxis (PEP) interventions, respectively. The primary outcome was the incidence density of leprosy by the end of 4 th year of annual follow-up. The preventive effect of the interventions was estimated by generalized estimating equations with possion distribution for family function and reported as incidence density ratio (IDR). Safety and economic evaluation of the interventions were done in parallel with the trial. Findings: Enrolled counties were randomly allocated to the rifapentine group (n=68, 2004 participants), the rifampicin group (n=71, 2609 participants), and the control group (n=68, 2837 participants). A total of 22 new leprosy cases occurred during the 4-year follow-up, 1 in the rifapentine group (incidence rate 0.14 per 1000 person-years), 4 in the rifampicin group (0.43 per 1000 person-years), and 17 in the control group (1.71 per 1000 person-years), respectively. The reduction of incidence density in the rifapentine and rifampicin groups was 92.6% (IDR 0.100, 95% CI 0.013 to 0.755, P=0.026), and 78.1% (IDR 0.265, 95% CI 0.089 to 0.794, P=0.018), respectively. No severe adverse event was observed in the three groups. In total, 12 incremental leprosy cases were prevented, resulting in an incremental cost-effectiveness ratio (ICER) of $175·7 in the rifapentine group and $20·3 in the rifampicin group per one additional prevented leprosy case.Interpretation: SDL or SDR is effective, safe, cost-efficient in preventing the development of leprosy in HHCs of leprosy patients under low endemic situations in China. Rifapentine could effectively reduce the incidence density of leprosy in HHCs, especially in HHCs of MB index cases, HHCs of new diagnosed index cases, and spouse of index cases.Trial Registration Details: This study was registered with www.chictr.org.cn. ChiCTR-IPR-15007075.Funding Information: This study was funded by the Ministry of Health of China (201502008) and CAMS Innovation Fund for Medical Science (2016-I2M-1-005, 2017-I2M-B&R-14).Declaration of Interests: We declare no competing interests.Ethics Approval Statement: The protocol and informed consent forms (2014-KY-003) were approved by the Research Ethics Board of the Hospital of Dermatology, the Chinese Academy of Medical Science, and the four other participating units. The written informed consent was required before enrolment.